Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. Papamichael K, et al. Among authors: vande casteele n. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1655-1668.e3. doi: 10.1016/j.cgh.2019.03.037. Epub 2019 Mar 27. Clin Gastroenterol Hepatol. 2019. PMID: 30928454 Free PMC article.
Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.
Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, Jürgens M, Ferrante M, Ballet V, Wollants WJ, Cleynen I, Van Steen K, Gils A, Rutgeerts P, Vermeire S, Van Assche G. Drobne D, et al. Among authors: vande casteele n. Clin Gastroenterol Hepatol. 2015 Mar;13(3):514-521.e4. doi: 10.1016/j.cgh.2014.07.027. Epub 2014 Jul 25. Clin Gastroenterol Hepatol. 2015. PMID: 25066841
Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, Vermeire S, Gils A, Feagan BG, Levesque BG, Vande Casteele N. Papamichael K, et al. Among authors: vande casteele n. Aliment Pharmacol Ther. 2015 Nov;42(10):1158-69. doi: 10.1111/apt.13402. Epub 2015 Sep 13. Aliment Pharmacol Ther. 2015. PMID: 26365281 Free article. Review.
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis.
Papamichael K, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, Claes K, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M. Papamichael K, et al. Among authors: vande casteele n. Clin Gastroenterol Hepatol. 2016 Apr;14(4):543-9. doi: 10.1016/j.cgh.2015.11.014. Epub 2015 Dec 8. Clin Gastroenterol Hepatol. 2016. PMID: 26681486
Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
Papamichael K, Rivals-Lerebours O, Billiet T, Vande Casteele N, Gils A, Ferrante M, Van Assche G, Rutgeerts PJ, Mantzaris GJ, Peyrin-Biroulet L, Vermeire S. Papamichael K, et al. Among authors: vande casteele n. J Crohns Colitis. 2016 Sep;10(9):1015-23. doi: 10.1093/ecco-jcc/jjw067. Epub 2016 Mar 28. J Crohns Colitis. 2016. PMID: 27022161
144 results